Envestnet Asset Management
RARE icon

Envestnet Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Envestnet Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$638K Sell
19,116
-465
-2% -$11.6K ﹤0.01% 3911
2026
Q1 		$410K Sell
19,581
-531
-3% -$12K ﹤0.01% 4069
2025
Q4 		$463K Sell
20,112
-4,921
-20% -$162K ﹤0.01% 3753
2025
Q3 		$753K Sell
25,033
-4,923
-16% -$148K ﹤0.01% 3496
2025
Q2 		$1.09M Buy
29,956
+1,698
+6% +$61.2K ﹤0.01% 3236
2025
Q1 		$1.02M Sell
28,258
-6,030
-18% -$251K ﹤0.01% 3189
2024
Q4 		$1.44M Sell
34,288
-2,836
-8% -$141K ﹤0.01% 2909
2024
Q3 		$2.06M Buy
37,124
+10,584
+40% +$539K ﹤0.01% 2637
2024
Q2 		$1.09M Sell
26,540
-2,688
-9% -$115K ﹤0.01% 2976
2024
Q1 		$1.36M Sell
29,228
-308
-1% -$14.5K ﹤0.01% 2815
2023
Q4 		$1.41M Sell
29,536
-6,320
-18% -$245K ﹤0.01% 2680
2023
Q3 		$1.28M Buy
35,856
+5,675
+19% +$225K ﹤0.01% 2628
2023
Q2 		$1.39M Buy
30,181
+4,868
+19% +$226K ﹤0.01% 2514
2023
Q1 		$1.02M Buy
25,313
+1,152
+5% +$49.4K ﹤0.01% 2668
2022
Q4 		$1.12M Buy
24,161
+1,733
+8% +$68.2K ﹤0.01% 2553
2022
Q3 		$929K Sell
22,428
-1,809
-7% -$93K ﹤0.01% 2627
2022
Q2 		$1.45M Buy
24,237
+420
+2% +$25.8K ﹤0.01% 2323
2022
Q1 		$1.73M Buy
23,817
+3,939
+20% +$274K ﹤0.01% 2290
2021
Q4 		$1.67M Buy
19,878
+2,709
+16% +$220K ﹤0.01% 2288
2021
Q3 		$1.55M Buy
17,169
+2,404
+16% +$217K ﹤0.01% 2259
2021
Q2 		$1.41M Sell
14,765
-1,927
-12% -$201K ﹤0.01% 2302
2021
Q1 		$1.9M Buy
16,692
+7,193
+76% +$979K ﹤0.01% 1966
2020
Q4 		$1.31M Buy
9,499
+1,829
+24% +$217K ﹤0.01% 2024
2020
Q3 		$630K Buy
7,670
+2,080
+37% +$172K ﹤0.01% 2337
2020
Q2 		$437K Buy
5,590
+664
+13% +$44K ﹤0.01% 2486
2020
Q1 		$219K Buy
+4,926
New +$256K ﹤0.01% 2693
2017
Q4 		– Sell
-287
Closed -$15K – 2994
2017
Q3 		$15K Sell
287
-369
-56% -$21.9K ﹤0.01% 2535
2017
Q2 		$40K Sell
656
-17
-3% -$1.02K ﹤0.01% 2432
2017
Q1 		$46K Buy
673
+43
+7% +$3.28K ﹤0.01% 2445
2016
Q4 		$44K Buy
+630
New +$44.7K ﹤0.01% 2486

Other funds holding RARE

Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Envestnet Asset Management's RARE Position: Q2 2026 in Review

Envestnet Asset Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 2.4% in Q2 2026, selling an estimated $11.6K and leaving 19,116 shares worth $638K. The position accounts for ﹤0.01% of the portfolio, ranked #3911.

Envestnet Asset Management first reported a position in RARE in Q4 2016 and has held it in 30 quarters since. The position peaked at $2.06M in Q3 2024. 74 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Envestnet Asset Management held 19,116 shares of Ultragenyx Pharmaceutical worth $638K as of Q2 2026.
  • Envestnet Asset Management sold 465 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $11.6K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3911 holding.
  • Envestnet Asset Management first reported a position in Ultragenyx Pharmaceutical in Q4 2016 and has held it in 30 quarters since.
  • Envestnet Asset Management's Ultragenyx Pharmaceutical position peaked at $2.06M in Q3 2024.
  • 74 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.